enx-104
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 17, 2025 (NCT07253324)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Dopamine D3 receptorANTAGONIST
DRD3 antagonist
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07253272 | Phase 1 | Feb 24, 2025 | Engrail Therapeutics INC, Parexel |
| NCT07253324 | Phase 1 | Feb 17, 2025 | Engrail Therapeutics INC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Engrail Therapeutics INC | For profit | 2 | 2 | 1 | 2025 |
| Parexel | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1